|
|
||||||||
Regular Article |
Received July 6, 2000; revised September 25, 2000; accepted October 30, 2000. From Mental Health Outcomes, Lewisville, Texas, and Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana. Address correspondence to Dr. Edell, Mental Health Outcomes, 1500 Waters Ridge Drive, Lewisville, TX 75057. e-mail: William_edell{at}horc.com
Behavioral/psychological symptoms of dementia (BPSD) affect caregiver burden and transition from home to hospital or long-term care. The authors examined change in BPSD for dementia patients (from hospital admission to discharge) who were prescribed haloperidol (n= 289), olanzapine (n=209), or risperidone (n=500). Olanzapine was associated with significantly greater overall improvement in BPSD (based on the Psychogeriatric Dependency Rating Scale total score) than risperidone or haloperidol. Olanzapine was significantly superior on measures of active-, verbal-, and passive-aggression and delusions/hallucinations to risperidone or haloperidol, and, on manipulative behavior and noisiness, to risperidone. Results support the effectiveness of olanzapine in improving several BPSD in hospitalized dementia patients.
Key Words: Antipsychotics Dementia Treatment Behavioral Symptoms
This article has been cited by other articles:
![]() |
References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text] |
||||
![]() |
M. Sajatovic, S. H. Friedman, J. Sabharwal, and C. R. Bingham Clinical Characteristics and Length of Hospital Stay among Older Adults with Bipolar Disorder, Schizophrenia or Schizoaffective Disorder, Depression, and Dementia J Geriatr Psychiatry Neurol, March 1, 2004; 17(1): 3 - 8. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |